NCT05554367 2026-03-18
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05111561 2026-03-17
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05554354 2026-03-03
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Terminated
NCT04439344 2025-11-19
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04324112 2025-11-10
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04322383 2025-08-26
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting